Vertex Pharmaceuticals Stock Forecast

Stock Price Forecast

According to 32 analysts polled by S&P Global, Vertex Pharmaceuticals stock has a consensus rating of "Buy" and an average price target of $592.36. The average 1-year stock price forecast is 8.27% higher than the current stock price, while the lowest is $350 (-36.03%) and the highest is $725 (+32.52%).

Price Target: $592.36 (+8.27%)

Analyst Consensus: Buy

Price Target

Chart

Target	Low	Average	Median	High
Price	$350	$592.36	$600	$725
Change	-36.03%	+8.27%	+9.67%	+32.52%

Analyst Ratings

The average analyst rating for Vertex Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Chart

Rating	Jun '26	Jul '26	Aug '26	Sep '26	Oct '26	Nov '26
Strong Buy	21	19	19	20	20	20
Buy	6	4	4	6	6	6
Hold	4	4	4	4	4	5
Sell	1	1	1	1	1	0
Strong Sell	1	1	1	1	1	1
Total	33	29	29	32	32	32

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Naz Rahman Maxim Group	Maxim Group	Buy Reiterates $575 → $620	Buy	Reiterates	$575 → $620	+13.33%	Nov 4, 2026
Eliana Merle Barclays	Barclays	Buy Maintains $617 → $626	Buy	Maintains	$617 → $626	+14.42%	Nov 4, 2026
Ananda Ghosh H.C. Wainwright	H.C. Wainwright	Buy Reiterates $641	Buy	Reiterates	$641	+17.17%	Nov 3, 2026
Evan Seigerman BMO Capital	BMO Capital	Buy Maintains $600 → $620	Buy	Maintains	$600 → $620	+13.33%	Nov 3, 2026
Tazeen Ahmad Bank of America Securities	Bank of America Securities	Buy Reiterates $667	Buy	Reiterates	$667	+21.92%	Nov 3, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

13.25B

from 12.00B

10.42%

from 12.00B

Revenue Next Year

14.63B

from 13.25B

10.38%

from 13.25B

EPS This Year

18.15

from 18.40

-1.33%

from 18.40

EPS Next Year

19.91

from 18.15

9.66%

from 18.15

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	7.57B	8.93B	9.87B	11.02B	12.00B	13.25B
Revenue Growth	22.06%	17.91%	10.51%	11.66%	8.90%	10.42%
Operating Income	3.89B	4.38B	4.31B	4.40B	4.69B	5.40B
Net Income	2.34B	3.32B	3.62B	-535.60M	3.95B	3.63B
EPS	-	-	-	-	18.40	18.15
EPS Growth	-	-	-	-	4,280.95%	-1.33%
Forward PE	16.42	18.83	24.44	22.66	22.61	30.13
Free Cash Flow	-	-	-	-	3.19B	6.27B
No. Analysts	-	-	-	-	-	25

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Chart

Revenue	2026	2027	2028
High	13.4B
Avg	13.3B
Low	13.2B

Revenue Growth

Chart

Revenue Growth	2026	2027	2028
High	11.7%
Avg	10.4%
Low	9.8%

EPS Forecast

Chart

EPS	2026	2027	2028
High	19.17
Avg	18.15
Low	17.75

EPS Growth

Chart

EPS Growth	2026	2027	2028
High	4.2%
Avg	-1.3%
Low	-3.5%